Medicus Pharma (NASDAQ:MDCX) said its SkinJect microneedle therapy showed encouraging results in a Phase 2 study evaluating the treatment for nodular basal cell carcinoma.
The SKNJCT-003 trial tested the company’s Doxorubicin Microneedle Array, a non-invasive therapy designed to treat skin cancer. In the 200-microgram dose cohort at Day 57, the treatment achieved 73% clinical clearance and 40% histological clearance, outperforming placebo and lower-dose groups.
Medicus Pharma said the results provide “decision-grade” data and expects to complete a full Clinical Study Report in the second quarter of 2026. The report will support a planned end-of-Phase-2 meeting with the U.S. Food and Drug Administration.
Management believes the stronger efficacy seen at the higher dose could support ongoing and future partnership discussions. The company’s strategy focuses on advancing assets through Phase 2 before pursuing licensing agreements or strategic partnerships for late-stage development and commercialization.
Despite the positive clinical progress, Medicus Pharma continues to face financial challenges, including a lack of revenue, widening losses and significant cash burn. Recent financing has improved liquidity but also increases reliance on external funding.
More about Medicus Pharma Ltd
Medicus Pharma develops precision-guided therapies aimed at non-invasive treatment approaches. Its pipeline focuses on technologies such as the Doxorubicin Microneedle Array for skin cancers, with the company seeking partnerships with larger pharmaceutical firms to advance later-stage development and commercialization.